Follow us on:
Breaking News
August 21, 2026
CP Direct: Friday Edition
Breaking News
Federal Equipment_CP_Leaderboard_8/21/26
Next Week at Contract Pharma
ProBio_Webinar_08-27-26_FeaturedContent

Halo Pharma to Activate Sterile Injectable Line in NJ

 
Halo Pharma to Activate Sterile Injectable Line in NJ

The $45 million investment expands domestic sterile manufacturing capacity for pharma and biotech clients.
Read More >>

Top Headlines

Friday Brief
Videos

The Friday Brief for August 21, 2026: Partners Sharpen Their Focus

Piramal Pharma buys a majority stake in Yapan Bio, and Emergent BioSolutions is restructuring.

SPONSOR

What Really Holds an Integrated CRO CDMO Program Together

Clinical supply chain is the bridge between development and clinical operations. Learn the people, processes, and systems that turn integrated services into coordinated execution. Free webinar, September 17 at 11 AM ET.

Breaking News

MedPharm Expands End-to-End Proteomic Analysis Capabilities with Olink Certification

Certification adds targeted multiplex protein biomarker analysis to MedPharm’s research and translational testing capabilities.

Breaking News

Genentech to Invest $750M in Oregon Manufacturing Site

New manufacturing facility to support pre-filled syringes, autoinjectors and future medicines.

SPONSOR

DMSO Grades, Purity, and Regulatory Assurance: Understanding Quality Differentiation and Manufacturing Traceability

Addressing quality and regulatory requirements for pharmaceutical applications.

ContractPharma_Conference_2026_650x250

Breaking News

Halo Pharma to Activate Sterile Injectable Line in NJ

The $45 million investment expands domestic sterile manufacturing capacity for pharma and biotech clients.

Features

Top 20 Pharma and BioPharma Companies

Ranking the Industry’s Leading Companies Shaping the Future of Pharma & BioPharma

Featured Resources

Solution Center SPOTLIGHT

ESTEVE CDMO

We are a leading provider of high-quality small-molecule APIs and pharmaceutical intermediates. With over 55 years of expertise and a proven track record in developing numerous new chemical entity (NCE) products across diverse therapeutic areas, we have established ourselves as a trusted partner for innovative pharmaceutical companies worldwide.

 

Solution Center SPOTLIGHT

Siegfried

Siegfried offers contract development and manufacturing of APIs, intermediates, and finished dosage forms. From early-phase development to commercial scale, its integrated approach ensures comprehensive services, including process development, registration, production, packaging, and logistics. Siegfried operates 13 facilities in 7 countries worldwide.